South Africa's biggest poultry producer Astral Foods swung to a full-year loss on Monday, as an ongoing electricity crisis and the country's worst bird flu outbreak cost the company 2 billion rand ($108.9 million). reut.rs/3R6Dwx5 reut.rs/3R6Dwx5

Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor. reut.rs/47GqnkU reut.rs/47GqnkU

Weight loss was the talk of this earnings season, making names such as Wegovy, Ozempic and Mounjaro the water-cooler discussion that companies across the globe could not ignore. reut.rs/3G5hNQG reut.rs/3G5hNQG

Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor. reut.rs/3R4z6b8 reut.rs/3R4z6b8

Demand for a diabetes medicine called Ozempic is soaring as people take it to shed pounds, leading to shortages in countries including Britain, Germany, Belgium and the United States. reut.rs/3umaD8h reut.rs/3umaD8h

Demand for a diabetes medicine called Ozempic is soaring as people take it to shed pounds, leading to shortages in countries including Britain, Germany, Belgium and the United States. reut.rs/47ipv6h reut.rs/47ipv6h

Demand for a diabetes medicine called Ozempic is soaring as people take it to shed pounds, leading to shortages in countries including Britain, Germany, Belgium and the United States. reut.rs/47jKF3Q reut.rs/47jKF3Q

The U.S. Food and Drug Administration on Friday approved the use of Medtronic's treatment device in a surgery called renal denervation in patients whose high blood pressure cannot be controlled by drugs, the company said. reut.rs/47AALuo reut.rs/47AALuo

Bayer said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi in the U.S. due to the presence of microbial contamination that was observed during routine stability testing. reut.rs/3SOQZvW reut.rs/3SOQZvW

Advisers to the U.S. health regulator said on Friday that data on Merck's chronic cough drug does not provide sufficient evidence to prove its clinical benefit for patients. reut.rs/3MR06YZ reut.rs/3MR06YZ

The U.S. Food and Drug Administration on Friday approved the use of Medtronic's treatment device in a surgery called renal denervation in patients whose high blood pressure cannot be controlled by drugs, the company said. reut.rs/3uk0OYz reut.rs/3uk0OYz

Bayer said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi in the U.S. due to the presence of microbial contamination that was observed during routine stability testing. reut.rs/49Hlvh6 reut.rs/49Hlvh6

The U.S. Food and Drug Administration (FDA) on Friday said it had identified the recall of B. Braun Medical Inc's medicine-delivering pump system as most serious. reut.rs/3sByn7V reut.rs/3sByn7V

Advisers to the U.S. health regulator said on Friday that data on Merck's chronic cough drug does not provide sufficient evidence to prove its clinical benefit for patients. reut.rs/3QNmlAn reut.rs/3QNmlAn

The U.S. Food and Drug Administration on Friday approved the use of Medtronic's treatment device in a surgery called renal denervation in patients whose high blood pressure cannot be controlled by drugs, the company said. reut.rs/3urOc1g reut.rs/3urOc1g

Bayer said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi in the U.S. due to the presence of microbial contamination that was observed during routine stability testing. reut.rs/46nGuCN reut.rs/46nGuCN

The U.S. Food and Drug Administration (FDA) on Friday said it had identified the recall of B. Braun Medical Inc's medicine-delivering pump system as most serious. reut.rs/3R2CeUW reut.rs/3R2CeUW

The U.S. health regulator's advisers said on Friday that data on Merck's chronic cough drug gefapixant does not provide sufficient evidence to prove its clinical benefit for patients. reut.rs/47j2hwK reut.rs/47j2hwK

Booming demand for newer weight-loss and diabetes drugs is expected to accelerate the rise in medical expenses for employers in the United States next year, staff health benefits consultant Mercer said on Friday. reut.rs/3G6CyMc reut.rs/3G6CyMc

Lonza's chairman has ruled out plans to use its capacity to fill syringes and provide final production steps for new obesity drugs even as rivals scramble for a share of the booming weight-loss market. reut.rs/46l9lYc reut.rs/46l9lYc